Augmentin Can be Questioned in India after Taiwan’s Ban

Augmentin, a GlaxoSmithKline’s (GSK), product was banned in Taiwan after the discovery of di-isodecyl phthalate’s (DIDP) presence in the drug in a little quantity. Now, the Indian physicians are concerned about the intake of the drug in the country.

GSK announced that the presence of DIDP is in less quantity. The quantity is lower than the one described dangerous by US medical experts.

Even after such announcement, the medical experts are worried about their presence in common painkillers. Patients take such antibiotics regularly for general ailment and are exposed to risk.

In India, annual sales of ¤240 crore is recorded every year due to the huge intake of Augmentin. Moreover, any step against the brand can lead to a huge loss to GSK along with decline in reputation, which is the largest existing brand in India.

The editor of Monthly Index, Medical Specialties, Chandra M Gulhati, said, “In Augmentin, amoxicillin and clavulanic acid are the active ingredients. All medicines contain inactive substances like coloring agents, binding agents and flavoring agents. The plasticizer was found in the flavoring agent in Taiwan”.

Gulhati illustrated on the scientific matters used in the medicines like only the active elements are shown on the label by the producers of the medicine and therefore, the procedure should be revised.